Modality
Bispecific Ab
MOA
CGRPant
Target
Aβ
Pathway
PD-1/PD-L1
CLLWilmsFSGS
Development Pipeline
Preclinical
~Aug 2021
→ ~Nov 2022
Phase 1
~Feb 2023
→ ~May 2024
Phase 2
Aug 2024
→ Jun 2030
Phase 2Current
NCT08458900
534 pts·CLL
2024-08→2030-06·Active
NCT08695506
778 pts·CLL
2025-01→2025-05·Completed
1,312 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-2410mo agoPh3 Readout· CLL
2030-06-264.2y awayPh3 Readout· CLL
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2/3
Active
P2/3
Complet…
Catalysts
Ph3 Readout
2025-05-24 · 10mo ago
CLL
Ph3 Readout
2030-06-26 · 4.2y away
CLL
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08458900 | Phase 2/3 | CLL | Active | 534 | FEV1 |
| NCT08695506 | Phase 2/3 | CLL | Completed | 778 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ |